[Colorectal cancer mass screening: present and future].
Hemoccult II is the only method of screening for colorectal cancer whose effectiveness in reducing specific mortality has been proved by randomized controlled trials. The first experience of French districts based on this strategy reproduced on a population scale the results of the experimental studies. Expanding screening in France to the general public is a public health priority. Large-scale media campaigns, which currently do not exist, could then be launched, and prevention opportunities seized. Immunological tests identifying the presence of blood in the stool have better sensitivity than the guaiac smear tests, especially for the diagnosis of adenomas and to a lesser extent, for that of cancers as a whole. These tests may constitute an alternative to guaiac tests, but are more expensive. Total colonoscopy, proposed every 10 years from the age of 50 years or once in a lifetime around the age of 60 years, is not a realistic method because of its cost and its risks. Sigmoidoscopies are under evaluation in several countries in randomized controlled trials but do not seem appropriate to either the epidemiologic trends of colorectal cancer or to the practice of endoscopy in France. Virtual colonoscopy is an attractive alternative to searching for blood in stool. The evaluation now underway should not interfere with the broad expansion of methods of proven efficacy. Virtual colonoscopy may face competition from numerous emerging techniques of endoscopic exploration of the colon, including the video-capsule. To obtain widespread participation in colorectal cancer screening, policy-makers must take the opinions of healthcare professionals and of the public into account. The medicoeconomic data will be a decisive factor in the choice between these new strategies.
Bretagne
Jean-François
JF
Service des maladies de l'appareil digestif, Hôpital Pontchaillou, Rennes. jean-francois.bretagne@chu-rennes.fr
Manfredi
Sylvain
S
Heresbach
Denis
D
D001291:Attitude of Health Personnel; D023881:Colonography, Computed Tomographic; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005544:Forecasting; D005602:France / Q000453:epidemiology; D006291:Health Policy; D006292:Health Priorities; D006301:Health Services Needs and Demand; D006801:Humans; D007159:Immunologic Tests; D008403:Mass Screening / Q000191:economics / Q000379:methods* / Q000639:trends; D009780:Occult Blood; D010342:Patient Acceptance of Health Care; D018579:Patient Selection; D011634:Public Health; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity